

No. SC100933

IN THE SUPREME COURT OF MISSOURI

◆

E.N.,
individually and on behalf of her minor child N.N., et al.,
Plaintiffs-Appellants,

v.

MIKE KEHOE,
in his official capacity as Governor of Missouri, et al.,
Defendants-Respondents.

◆

On Appeal from the Circuit Court of Cole County
Case No. 23AC-CC04530
Hon. R. Craig Carter

**BRIEF OF THE STATES OF ALABAMA, ALASKA, ARKANSAS, FLORIDA,
GEORGIA, IDAHO, INDIANA, IOWA, KANSAS, KENTUCKY, LOUISIANA,
MISSISSIPPI, MONTANA, NEBRASKA, NORTH DAKOTA, OHIO, OKLAHOMA,
SOUTH CAROLINA, SOUTH DAKOTA, TENNESSEE, TEXAS, UTAH, VIRGINIA,
WEST VIRGINIA, AND WYOMING AS *AMICI CURIAE*
SUPPORTING RESPONDENTS**

Timothy Belz, #31808
CLAYTON PLAZA LAW GROUP, L.C.
112 South Hanley, Second Floor
St. Louis, Missouri 63105-3418
Phone: (314) 726-2800
Fax: (314) 863-3821
tbelz@olblaw.com

Steve Marshall
Attorney General
A. Barrett Bowdre*
Principal Deputy Solicitor General
STATE OF ALABAMA
OFFICE OF THE ATTORNEY GENERAL
501 Washington Ave.
Montgomery, AL 36130
(334) 242-7300
Barrett.Bowdre@AlabamaAG.gov

*Application for *pro hac vice*
admission forthcoming

(additional counsel listed after signature page)

TABLE OF CONTENTS

TABLE OF CONTENTS	i
TABLE OF AUTHORITIES.....	iii
INTRODUCTION AND INTEREST OF <i>AMICI CURIAE</i>	1
STATEMENT OF CONSENT.....	4
JURISDICTIONAL STATEMENT	4
STATEMENT OF FACTS.....	4
ARGUMENT.....	4
I. WPATH Crafted SOC-8 As A Political And Legal Document.	4
A. WPATH Used SOC-8 to Advance Political and Legal Goals.	5
B. WPATH Changed Its Treatment Recommendations Based on Political Concerns.....	8
II. WPATH Did Not Follow The Principles Of Evidence-Based Medicine It Said It Followed.....	12
A. WPATH Failed to Properly Manage Conflicts of Interest.....	12
B. WPATH Was Not Transparent in How It Used GRADE.	15
C. WPATH Hindered Publication of Evidence Reviews.	18
D. WPATH Recommends Castration as “Medically Necessary” for “Eunuchs.”.....	20
III. WPATH Acts Like An Advocacy Organization, Not A Medical One.	22
CONCLUSION	26

ADDITIONAL COUNSEL	28
CERTIFICATE OF SERVICE AND COMPLIANCE	29

TABLE OF AUTHORITIES

Cases

<i>Dent v. West Virginia</i> , 129 U.S. 114 (1889)	1
<i>Eknes-Tucker v. Governor of Ala.</i> , 80 F.4th 1205 (11th Cir. 2023).....	2
<i>Eknes-Tucker v. Marshall</i> , 603 F. Supp. 3d 1131 (M.D. Ala. 2022).....	2

Other Authorities

Abigail Shrier, <i>Top Trans Doctors Blow the Whistle on “Sloppy” Care</i> , THE FREE PRESS (Oct. 4, 2021), https://perma.cc/R7M3-XTQ3	25
Azeen Ghorayshi, <i>Biden Officials Pushed to Remove Age Limits for Trans Surgery</i> , <i>Documents Show</i> , N.Y. TIMES (June 25, 2024), https://perma.cc/RP5L-QFD9	3
Azeen Ghorayshi, <i>U.S. Study on Puberty Blockers Goes Unpublished Because of</i> <i>Politics, Doctor Says</i> , N.Y. Times (Oct. 23, 2024), https://perma.cc/8M5A-4M3W	4
Br. of Alabama and 22 Other States as <i>Amici Curiae</i> Supporting Appellants, <i>Doe v. Surgeon General, State of Florida</i> , No. 24-11996 (11th Cir. argued Jan. 15, 2025).....	3
C. Ronny Cheung <i>et al.</i> , <i>Gender Medicine and the Cass Review: Why Medicine and the</i> <i>Law Make Poor Bedfellows</i> , ARCH. DIS. CHILD 1 (Oct. 2024), https://perma.cc/X7CH- NM7U	24
Defendants' Evidentiary Exhibits in Support of Summary Judgment, <i>Boe v. Marshall</i> , 2:22-cv-184 (M.D. Ala.), https://www.alabamaag.gov/boe-v-marshall	<i>passim</i>
Dep’t of Heath and Human Servs., <i>Treatment for Pediatric Gender Dysphoria:</i> <i>Review of Evidence and Best Practices</i> (May 1, 2025), https://perma.cc/F236-84DW	1
E. Coleman <i>et al.</i> , <i>Standards of Care for the Health of Transgender & Gender Diverse</i> <i>People, Version 8</i> , INT’L J. TRANSGENDER HEALTH (2022), https://perma.cc/Y9G6-TP3M	<i>passim</i>

E. Coleman, <i>Standards of Care, Version 7</i> , 13 INT’L J. OF TRANSGENDERISM 1 (2012), https://perma.cc/T8J7-W3WC	9
Genevieve Gluck, <i>Top Trans Medical Association Collaborated With Castration, Child Abuse Fetishists</i> , REDUXX (May 17, 2022), https://perma.cc/5DWF-MLRU	21
Helen Lewis, <i>The Liberal Misinformation Bubble About Youth Gender Medicine</i> , THE ATLANTIC (June 29, 2025), https://perma.cc/R4TZ-LS32	3
Howard Balshem <i>et al.</i> , <i>GRADE Guidelines</i> , 64 J. CLINICAL EPIDEMIOLOGY 401 (2011), https://perma.cc/2KDY-6BW5	17
Institute of Medicine (National Academies of Medicine), <i>Clinical Practice Guidelines We Can Trust</i> (2011), https://perma.cc/7SA9-DAUM	13, 14
Joint Letter from USPATH and WPATH (Oct. 12, 2022), https://perma.cc/X7ZN-G6FS	25
Kellan Baker <i>et al.</i> , <i>Hormone Therapy, Mental Health, and Quality of Life</i> , 5 J. ENDOCRINE SOCIETY 1 (2021).....	20
L. Wilson, <i>Effects of Antiandrogens on Prolactin Levels Among Transgender Women</i> , 21 INT’L J. OF TRANSGENDER HEALTH 391 (2020).....	20
Ling Yao <i>et. al.</i> , <i>Discordant and Inappropriate Discordant Recommendations</i> , BMJ (2021), https://perma.cc/W7XN-ZELX	18
Nicholas Confessore, <i>How the Transgender Rights movement Bet on the Supreme Court and Lost</i> , N.Y. TIMES (June 19, 2025), https://perma.cc/L5A6-ZVAW	3
<i>Research into Trans Medicine Has Been Manipulated</i> , THE ECONOMIST (June 27, 2024), https://perma.cc/A942-J2DY	3
Steve Marshall, <i>WPATH, ‘Transgender Healthcare,’ and the Supreme Court</i> , WALL STREET J. (Dec. 2, 2024), https://perma.cc/S74A-AFAM	3
World Health Organization, <i>Handbook for Guideline Development</i> (2012)	12, 13
WPATH and USPATH Comment on the Cass Review (May 17, 2024), https://perma.cc/B2TU-ALSR	24
WPATH, <i>Methodology for the Development of SOC8</i> , https://perma.cc/QD95-754H	16

Wylie C. Hembree et al., *Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline*,
102 J. CLIN. ENDOCRINOL. METAB. 3869 (2017), <https://perma.cc/NQK3-HYAV> 1

INTRODUCTION AND INTEREST OF *AMICI CURIAE*

Amici Curiae are the States of Alabama, Alaska, Arkansas, Florida, Georgia, Idaho, Indiana, Iowa, Kansas, Kentucky, Louisiana, Mississippi, Montana, Nebraska, North Dakota, Ohio, Oklahoma, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, West Virginia, and Wyoming.¹

Amici regulate healthcare. They have done so for as long as they have existed. *See Dent v. West Virginia*, 129 U.S. 114, 121-24 (1889). And like Missouri, in recent years *amici* States have been forced to regulate an area of medicine that the medical community has failed to self-regulate: the provision of sex-change procedures to minors. So *amici* are familiar with Plaintiffs’ argument here: that “well-established, widely accepted guidelines,” supported “by the major medical organizations in the United States,” recommend puberty blockers, cross-sex hormones, and surgical interventions as “medically necessary” care for kids suffering from gender-related psychological distress. Plfs’ Op. Br. 25-27. As Plaintiffs note in their brief, the “guidelines” they depend on are promulgated by the World Professional Association for Transgender Health (WPATH) and the Endocrine Society—whose guidelines were co-authored by WPATH.² *Id.* at 24.

¹ No party or party’s counsel authored this brief in whole or in part, and no one other than *amici* contributed to its preparation or submission.

² Wylie C. Hembree et al., *Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline*, 102 J. CLIN. ENDOCRINOL. METAB. 3869, 3869 (2017), <https://perma.cc/NQK3-HYAV> (listing WPATH as co-sponsor); *see also* Dep’t of Health and Human Servs., *Treatment for Pediatric Gender Dysphoria: Review of Evidence and Best Practices* 133 (May 1, 2025), <https://perma.cc/F236-84DW> (noting that the WPATH and Endocrine Society guidelines were “closely linked

What Plaintiffs fail to note is that these guidelines have been thoroughly discredited. In 2022, shortly after the Alabama legislature passed a law prohibiting pediatric sex-change procedures, plaintiffs there sought a preliminary injunction based on the promise that WPATH used the “best available science” to develop its “standard of care.” *See* Plaintiffs’ PI Mem., *Boe v. Marshall*, No. 2:22-cv-184 (M.D. Ala. 2022), Doc. 8 at 12-13, 16. The district court believed them. While acknowledging that “[k]nown risks” of transitioning treatments “include loss of fertility and sexual function,” the court preliminarily enjoined enforcement of Alabama’s law because “WPATH recognizes transitioning medications as established medical treatments and publishes a set of guidelines for treating gender dysphoria in minors with these medications.” *Eknes-Tucker v. Marshall*, 603 F. Supp. 3d 1131, 1139, 1151 (M.D. Ala. 2022), *rev’d sub nom. Eknes-Tucker v. Governor of Ala.*, 80 F.4th 1205 (11th Cir. 2023), *reh’g en banc denied*, 114 F.4th 1241 (11th Cir. 2024).

Alabama then sought and obtained court-ordered discovery from WPATH to test the court’s deference.³ Doing so unveiled a tragic medical scandal. Internal documents from WPATH showed that the organization crafted its latest Standards of Care—SOC-8, published in 2022—as “a tool for our attorneys to use in defending access to care.”⁴ Its

through overlapping authors and with WPATH acting as a sponsor for the development of ES guidelines”).

³ *See* Order, *Boe*, 2:22-cv-184 (M.D. Ala. Mar. 27, 2023), Doc. 263.

⁴ Defendants’ Ex. 181 at 75, *Boe*, 2:22-cv-184 (M.D. Ala.), Doc. 700-10.

Throughout this brief, *amici* will reference evidence that Alabama submitted to the court in *Boe*. Citations will be by exhibit number followed by the docket entry in parenthesis and the internal page number following the colon. *E.g.*, Ex.181 (Doc.700-10):75. Exhibits are available online: <https://www.alabamaag.gov/boe-v-marshall/>.

evidence-review team “found little to no evidence about children and adolescents.”⁵ Some SOC-8 authors opted *out* of the evidence-review process due to “concerns, echoed by the social justice lawyers we spoke with, ... that evidence-based review reveals little or no evidence and puts us in an untenable position in terms of affecting policy or winning lawsuits.”⁶ And Admiral Rachel Levine, the former Assistant Secretary for Health at HHS, demanded that WPATH remove *all* age limits for chemical treatments, chest surgeries, and even surgeries to remove children’s genitals from SOC-8. After some initial consternation “about allowing US politics to dictate international professional clinical guidelines,”⁷ WPATH obliged.

This evidence became public last summer and has been covered in—and substantiated by—deeply reported pieces in the *New York Times*, *The Economist*, *The Atlantic*, and elsewhere.⁸ And Plaintiffs’ counsel are well aware of this evidence, having been involved in other cases where it has been discussed.⁹ Three of their expert witnesses—Dr. Janssen,

⁵ Ex.173(Doc.560-23):22.

⁶ Ex.174(Doc.560-24):1-2.

⁷ Ex.186 (Doc.700-15):32.

⁸ See, e.g., Azeen Ghorayshi, *Biden Officials Pushed to Remove Age Limits for Trans Surgery, Documents Show*, N.Y. TIMES (June 25, 2024), <https://perma.cc/RP5L-QFD9>; Nicholas Confessore, *How the Transgender Rights Movement Bet on the Supreme Court and Lost*, N.Y. TIMES (June 19, 2025), <https://perma.cc/L5A6-ZVAW>; *Research into Trans Medicine Has Been Manipulated*, THE ECONOMIST (June 27, 2024), <https://perma.cc/A942-J2DY>; Helen Lewis, *The Liberal Misinformation Bubble About Youth Gender Medicine*, THE ATLANTIC (June 29, 2025), <https://perma.cc/R4TZ-LS32>; see also Steve Marshall, *WPATH, ‘Transgender Healthcare,’ and the Supreme Court*, WALL STREET J. (Dec. 2, 2024), <https://perma.cc/S74A-AFAM>.

⁹ See, e.g., Br. of Alabama and 22 Other States as *Amici Curiae* Supporting Appellants, *Doe v. Surgeon General, State of Florida*, No. 24-11996 (11th Cir. argued Jan. 15, 2025).

Dr. Shumer, and Dr. Antommara—even served as expert witnesses in Alabama’s case and thus had direct access to the discovery there. (Another expert, Dr. Johanna Olson-Kennedy, politicized her work without the help of WPATH, admitting to the *New York Times* that she “had not published a long-awaited study of puberty-blocking drugs” because she did not want the results to be “weaponized” by critics of pediatric sex-change procedures.¹⁰)

And still Plaintiffs tell this Court that the WPATH standards are reliable and that the trial court erred by rejecting them. But it is Plaintiffs who chose to build their case on a faulty cornerstone. This Court should affirm.

STATEMENT OF CONSENT

All parties consented to the timely filing of this brief.

JURISDICTIONAL STATEMENT

Amici adopt the jurisdictional statement in Respondents’ brief.

STATEMENT OF FACTS

Amici adopt the statement of facts in Respondents’ brief.

ARGUMENT

I. WPATH Crafted SOC-8 As A Political And Legal Document.

WPATH published Standards of Care 8 in September 2022.¹¹ Dr. Eli Coleman, a sexologist at the University of Minnesota, chaired the guideline committee, and WPATH

¹⁰ Azeen Ghorayshi, *U.S. Study on Puberty Blockers Goes Unpublished Because of Politics, Doctor Says*, N.Y. Times (Oct. 23, 2024), <https://perma.cc/8M5A-4M3W>.

¹¹ See E. Coleman et al., *Standards of Care for the Health of Transgender & Gender Diverse People, Version 8*, 23 INT’L J. TRANSGENDER HEALTH (2022), <https://perma.cc/Y9G6-TP3M>.

hired an outside evidence-review team, led by Dr. Karen Robinson at Johns Hopkins University, to conduct systematic evidence reviews for authors to use in formulating their recommendations.¹² Two WPATH presidents, Dr. Walter Bouman, a clinician at the Nottingham Centre for Transgender Health in England, and Dr. Marci Bowers, a surgeon in California who has performed over 2,000 transitioning vaginoplasties, oversaw development and publication of the guideline.

A. WPATH Used SOC-8 to Advance Political and Legal Goals.

WPATH selected 119 authors—all existing WPATH members—to contribute to SOC-8.¹³ According to Dr. Bowers, it was “important” for each author “to be an advocate for [transitioning] treatments before the guidelines were created.”¹⁴ Many authors regularly served as expert witnesses to advocate for sex-change procedures in court; Dr. Coleman testified that he thought it was “ethically justifiable” for those authors to “advocate for language changes [in SOC-8] to strengthen [their] position in court.”¹⁵ Other contributors seemed to concur. One wrote: “My hope with these SoC is that they land in such a way as to have serious effect in the law and policy settings that have affected us so much recently; even if the wording isn’t quite correct for people who have the background you and I have.”¹⁶ Another chimed in: “It is abundantly clear to me when I go to court on behalf of

¹² *Id.* at S248-49.

¹³ *Id.* at S248-49; *see* Ex.21(Doc.700-3):201:2–223:24.

¹⁴ Ex.18(Doc.564-8):121:7-11.

¹⁵ Ex.21(Doc.700-3):158:17-25.

¹⁶ Ex.184(Doc.700-13):24.

TGD [transgender and gender-diverse] individuals” that “[t]he wording of our section for Version 7 has been critical to our successes, and I hope the same will hold for Version 8.”¹⁷

Perhaps for this reason—and because it knew that “we will have to argue it in court at some point”¹⁸—WPATH commissioned a legal review of SOC-8 and was in regular contact with movement attorneys.¹⁹ Dr. Bouman noted the oddity: “The SOC8 are clinical guidelines, based on clinical consensus and the latest evidence based medicine; [I] don’t recall the Endocrine Guidelines going through legal reviews before publication, or indeed the current SOC?”²⁰ The WPATH Executive Committee discussed various options for the review—“ideas; ACLU, TLDEF, Lambda Legal...”²¹—before apparently settling on the senior director of transgender and queer rights at GLAD to conduct the review.²²

Authors were explicit in their desire to tailor SOC-8 to ensure coverage for an “individual’s embodiment goals,”²³ whatever they might be. As Dr. Dan Karasic, one of the plaintiffs’ experts in Alabama’s case, explained to other contributors: “Medical necessity is at the center of dozens of lawsuits in the US right now”;²⁴ “I cannot overstate the

¹⁷ Ex.184(Doc.700-13):15.

¹⁸ Ex.182(Doc.700-11):152.

¹⁹ Ex.4(Doc.557-4):vi.

²⁰ Ex.182(Doc.700-11):151.

²¹ Ex.184(Doc.700-13):14.

²² SOC-8, *supra* note 11, at S177.

²³ Ex.180(Doc.700-9):11.

²⁴ *Id.* at 64.

importance of SOC 8 getting this right at this important time.”²⁵ Another author was more succinct: “[W]e need[] a tool for our attorneys to use in defending access to care.”²⁶

At Dr. Karasic’s urging, WPATH included a whole section in SOC-8 on “medical necessity” and took to heart his advice to list the “treatments in an expansive way.”²⁷ It assigned the designation to a whole host of interventions, including but “not limited to hysterectomy,” with or without “bilateral salpingo-oophorectomy”; “bilateral mastectomy, chest reconstruction or feminizing mammoplasty”; “phalloplasty and metoidioplasty, scrotoplasty, and penile and testicular prostheses, penectomy, orchiectomy, vaginoplasty, and vulvoplasty”; “gender-affirming facial surgery and body contouring”; and “puberty blocking medication and gender-affirming hormones.”²⁸

One author aptly concluded of the statement: “I think it is clear as a bell that the SOC8 refers to the necessity of treatment (in its broadest sense) for their gender dysphoria (small ‘d’); because it refers to the symptom of distress—which is a very very very broad category and one that any ‘goodwilling’ clinician can use for this purpose (or: in the unescapable medical lingo we, as physicians are stuck with: those who fulfil a diagnosis of Gender Dysphoria and Gender Incongruence as per APA/WHO).”²⁹

WPATH also made sure to sprinkle the “medically necessary” moniker throughout the guideline, even when doing so revealed it had put the cart before the horse. The

²⁵ Ex.181(Doc.700-10):43.

²⁶ *Id.* at 75.

²⁷ SOC-8, *supra* note 11, at S18.

²⁸ *Id.*

²⁹ Ex.181(Doc.700-10):36 (second closed parenthesis added).

adolescent chapter, for instance, notes that “[a] key challenge in adolescent transgender care is the quality of evidence evaluating the effectiveness of medically necessary gender-affirming medical and surgical treatments,”³⁰ but WPATH never paused to ask (or answer) how such treatments can be considered “medically necessary” if the “quality of evidence” supporting their use is so deficient. At least some authors tacitly acknowledged the question and made sure they wouldn’t have to answer it—by following the advice of “social justice lawyers” to avoid conducting systematic evidence reviews lest they “reveal[] little or no evidence and put[] us in an untenable position in terms of affecting policy or winning lawsuits.”³¹ Others just sought to massage the guideline’s language to avoid “empower[ing]” those concerned that the evidence did not support transitioning treatments,³² all while authors and WPATH leaders raised such concerns internally.³³

B. WPATH Changed Its Treatment Recommendations Based on Political Concerns.

Outside political actors also influenced SOC-8. Most notably, Admiral Levine, the former Assistant Secretary for Health, met regularly with WPATH leaders, “eager to learn when SOC 8 might be published.”³⁴ A few months before SOC-8 was to be published in

³⁰ SOC-8, *supra* note 11, at S45-46.

³¹ Ex.174(Doc.560-24):1-2.

³² Ex.184(Doc.700-13):55.

³³ *E.g.*, Ex.176(Doc.700-5):67-68 (Dr. Bowers admitting that “no long-term studies” exist for puberty blockers); Ex.180(Doc.700-9):21 (author admitting that “most of the recommendation statements in SOC8 are not PICO format”—meaning were not supported by systematic evidence reviews—“but consensus based or based on weak evidence”); Ex.180(Doc.700-9):63 (WPATH leader: “My understanding is that a global consensus on ‘puberty blockers’ does not exist”); *see generally* Ex.4(Doc.557-4):i-iv.

³⁴ Ex.184(Doc.700-13):54.

September 2022 (and long after the public comment period had closed that January³⁵), WPATH sent Levine an “Embargoed Copy – For Your Eyes Only” draft of SOC-8 that had been “completed” and sent to the publisher for proofreading and typesetting.³⁶ The draft included a departure from Standards of Care 7, which, except for so-called “top surgeries,” restricted transitioning surgeries to patients who had reached the “[a]ge of majority in a given country.”³⁷ The draft SOC-8 relaxed the age minimums: 14 for cross-sex hormones, 15 for “chest masculinization” (i.e., mastectomy), 16 for “breast augmentation, facial surgery (including rhinoplasty, tracheal shave, and genioplasty),” 17 for “metoidioplasty, orchiectomy, vaginoplasty, hysterectomy and fronto-orbital remodeling,” and 18 for “phalloplasty.”³⁸

After reviewing the draft, Levine’s office contacted WPATH with a political concern: that the listing of “specific minimum ages for treatment,” “under 18, will result in devastating legislation for trans care.”³⁹ WPATH leaders met with Levine to discuss the age recommendations.⁴⁰ Levine’s solution was simple: “She asked us to remove them.”⁴¹

The authors of the adolescent chapter wrestled with how to respond to the request:

- “I really think the main argument for ages is access/insurance. So the irony is that the fear is that ages will spark political attacks on access. I don’t know how I feel

³⁵ See Ex.187(Doc.700-16):4-5.

³⁶ Ex.170(Doc.700-4):61-64.

³⁷ E. Coleman, *Standards of Care, Version 7*, 13 INT’L J. TRANSGENDERISM 1, 25-27 (2012), <https://perma.cc/T8J7-W3WC>.

³⁸ Ex.170(Doc.700-4):143.

³⁹ Ex.186 (Doc.700-15):28.

⁴⁰ See Ex.186 (Doc.700-15):11, 17; Ex.21(Doc.700-3):287:5–288:6.

⁴¹ Ex.186 (Doc.700-15):11.

about allowing US politics to dictate international professional clinical guidelines that went through Delphi.”⁴²

- “I’m also curious how the group feels about us making changes based on current US politics.... I agree about listening to Levine.”⁴³
- “I think it’s safe to say that we all agree and feel frustrated (at minimum) that these political issues are even a thing and are impacting our own discussions and strategies.”⁴⁴

WPATH initially told Levine that it “could not remove [the age minimums] from the document” because the recommendations had already been approved by SOC-8’s “Delphi” consensus process.⁴⁵ (Indeed, Dr. Coleman said that consensus was “[t]he only evidence we had” for the recommendations.⁴⁶) But, WPATH continued, “we heard your comments regarding the minimal age criteria” and, “[c]onsequently, we have made changes to the SOC8” by downgrading the age “recommendation” to a “suggestion.”⁴⁷ Unsatisfied, Levine immediately requested—and received—more meetings with WPATH.⁴⁸

Following Levine’s intervention, and days before SOC-8 was to be published, pressure from the American Academy of Pediatrics (AAP) tipped the scales when it threatened to oppose SOC-8 if WPATH did not remove the age minimums.⁴⁹ WPATH leaders initially balked. One of the co-chairs of SOC-8 complained that “[t]he AAP guidelines ... have a

⁴² *Id.* at 32.

⁴³ *Id.*

⁴⁴ *Id.* at 33.

⁴⁵ *Id.* at 17.

⁴⁶ *Id.* at 57.

⁴⁷ *Id.* at 17.

⁴⁸ *See* Ex.18(Doc.564-8):226:8–229:18; Ex.186 (Doc.700-15):73, 88-91.

⁴⁹ Ex.187(Doc.700-16):13-14, 109.

very weak methodology, written by few friends who think the same.”⁵⁰ But the political reality soon set in: AAP was “a MAJOR organization,” and “it would be a major challenge for WPATH” if AAP opposed SOC-8.⁵¹ WPATH thus “remove[d] the ages.”⁵²

That is concerning enough. But perhaps even more worrisome is what the episode reveals. *First*, it shows that politicians and AAP sought, and WPATH agreed, to make changes in a clinical guideline recommending irreversible sex-change procedures *for kids* based purely on political considerations. Dr. Coleman was clear in his deposition that WPATH removed the age minimums without allowing authors to vote on the change and “without being presented any new science of which the committee was previously unaware.”⁵³

Second, as soon as WPATH made the change, it treated the decision as “highly, highly confidential.”⁵⁴ Dr. Bowers encouraged contributors to submit to “centralized authority” so there would not be “differences that can be exposed.”⁵⁵ “[O]nce we get out in front of our message,” Bowers urged, “we all need to support and reverberate that message so that the misinformation drone is drowned out.”⁵⁶

Having decided the strategy, Bowers then crafted the message, circulating internally the “gist of my[] response to Reuters” about the missing age minimums: “[S]ince the open

⁵⁰ *Id.* at 100.

⁵¹ *Id.* at 191.

⁵² *Id.* at 338.

⁵³ Ex.21(Doc.700-3):293:25–295:16.

⁵⁴ Ex.188(Doc.700-17):152.

⁵⁵ Ex.177(Doc.700-6):124.

⁵⁶ *Id.* at 119.

comment period, a great deal of input has been received and continued to be received until the final release. [I] feel the final document puts the emphasis back on individualized patient care rather than some sort of minimal final hurdle that could encourage superficial evaluations and treatments.”⁵⁷ Another leader responded: “I like this. Exactly—individualized care is the best care—that’s a positive message and a strong rationale for the age change.”⁵⁸ Apparently, it didn’t matter that the explanation itself was “misinformation”; as Dr. Bowers explained in a similar exchange, “it is a balancing act between what i feel to be true and what we need to say.”⁵⁹

II. WPATH Did Not Follow The Principles Of Evidence-Based Medicine It Said It Followed.

At the back of SOC-8 is an appendix with the methodology WPATH said it employed.⁶⁰ It proclaims that WPATH managed conflicts of interest, used the GRADE framework to tailor recommendation statements based on strength of evidence, and engaged an evidence-review team to conduct systematic literature reviews for SOC-8.⁶¹ Discovery revealed a different story.

A. WPATH Failed to Properly Manage Conflicts of Interest.

WPATH cites two standards it said it used to manage conflicts of interest: one from the National Academies of Medicine and the other from the World Health Organization.⁶²

⁵⁷ Ex.188(Doc.700-17):113.

⁵⁸ *Id.*

⁵⁹ Ex.177(Doc.700-6):102.

⁶⁰ *See* SOC-8, *supra* note 11, at S247-51.

⁶¹ *Id.*

⁶² *Id.* at S247.

Both standards generally recognize that the experts best equipped for creating practice guidelines are those at arm's length from the services at issue—sufficiently familiar with the topic, but *not* professionally engaged in performing, researching, or advocating for the practices under review.⁶³

At the same time, the standards recognize that a guideline committee typically benefits from *some* involvement by clinicians who provide the services at issue.⁶⁴ Accordingly, they suggest ways for committees to benefit from conflicted clinicians while limiting their involvement. The standard from the National Academies recommends that “[m]embers with [conflicts of interest] should represent *not more than a minority* of the [guideline development group].”⁶⁵

WPATH largely ignored these standards. From the get-go, it expressly limited SOC-8 authorship to existing WPATH members—clinicians and other professionals (and non) who were *already* enthusiastic about transitioning treatments.⁶⁶ As Dr. Bowers testified, it was “important for someone to be an advocate for [transitioning] treatments before the guidelines were created.”⁶⁷

Dr. Bowers’s involvement in SOC-8 offers a good illustration of the lack of real conflict checks. According to the National Academies, a “conflict of interest” is “[a]

⁶³ *Id.*; Institute of Medicine (National Academies of Medicine), *Clinical Practice Guidelines We Can Trust* 81-93 (2011), <https://perma.cc/7SA9-DAUM>; World Health Organization, *Handbook for Guideline Development* 19-23 (2012).

⁶⁴ Institute of Medicine, *supra* note 63, at 83.

⁶⁵ *Id.* (emphasis added).

⁶⁶ SOC-8, *supra* note 11, at S248; *see* Ex.21(Doc.700-3):201:2–223:24.

⁶⁷ Ex.18(Doc.564-8):121:7-11.

divergence between an individual's private interests and his or her professional obligations such that an independent observer might reasonably question whether the individual's professional actions or decisions are motivated by personal gain, such as financial, academic advancement, clinical revenue streams, or community standing.”⁶⁸ Bowers should have been subject to that standard, serving not only as a member of the Board that oversaw and approved SOC-8 but as an author of the chapter tasked with evaluating the evidence for transitioning surgeries.

So it is notable that Bowers made “more than a million dollars” in 2023 from providing transitioning surgeries, but said it would be “absurd” to consider that a conflict worth disclosing or otherwise accounting for as part of SOC-8.⁶⁹ That was WPATH's public position as well: It assured readers that “[n]o conflicts of interest were deemed significant or consequential” in crafting SOC-8.⁷⁰

Privately, WPATH leaders knew everything was not up to par. Dr. Coleman admitted that “most participants in the SOC-8 process had financial and/or nonfinancial conflicts of interest.”⁷¹ Another author agreed: “Everyone involved in the SOC process has a non-financial interest.”⁷² Dr. Robinson, the chair of the evidence-review team, said the same: She “expect[ed] many, if not most, SOC-8 members to have competing interests.”⁷³ She

⁶⁸ Institute of Medicine, *supra* note 63, at 78.

⁶⁹ Ex.18(Doc.564-8):37:1-13, 185:25–186:9.

⁷⁰ SOC-8, *supra* note 11, at S177.

⁷¹ Ex.21(Doc.700-3):230:17-23.

⁷² Ex.174(Doc.560-24):7.

⁷³ Ex.166(Doc.560-16):1.

even had to inform WPATH—belatedly—that “[d]isclosure, and any necessary management of potential conflicts, should take place *prior* to the selection of guideline members.”⁷⁴ “Unfortunately,” she lamented, “this was not done here.”⁷⁵ No matter: SOC-8 proclaims the opposite (“Conflict of interests were reviewed as part of the selection process”⁷⁶), and Dr. Coleman testified that he did not know of any author removed from SOC-8 due to a conflict.⁷⁷

B. WPATH Was Not Transparent in How It Used GRADE.

WPATH boasted that it used a process “adapted from the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) framework” for “developing and presenting summaries of evidence” using a “systematic approach for making clinical practice recommendations.”⁷⁸ According to WPATH, Dr. Robinson’s evidence-review team was to conduct systematic evidence reviews, “assign[] evidence grades using the GRADE methodology,” and “present[] evidence tables and other results of the systematic review” to SOC-8 authors.⁷⁹

Chapter authors were then to grade the recommendation statements based on the evidence.⁸⁰ Per WPATH, “strong recommendations”—“we recommend”—were only for situations where “the evidence is high quality,” “a high degree of certainty [that] effects

⁷⁴ *Id.* (emphasis added).

⁷⁵ *Id.*

⁷⁶ SOC-8, *supra* note 11, at S177.

⁷⁷ Ex.21(Doc.700-3):232:13-15.

⁷⁸ SOC-8, *supra* note 11, at S250.

⁷⁹ *Id.* at S249-50.

⁸⁰ *Id.* at S250.

will be achieved,” “few downsides,” and “a high degree of acceptance among providers.”⁸¹ On the other hand, “[w]eak recommendations”—“we suggest”—were for when “there are weaknesses in the evidence base,” “a degree of doubt about the size of the effect that can be expected,” and “varying degrees of acceptance among providers.”⁸² To “help readers distinguish between recommendations informed by systematic reviews and those not,” recommendations were to “be followed by certainty of evidence for those informed by systematic literature reviews”:

++++	strong certainty of evidence
+++	moderate certainty of evidence
++	low certainty of evidence
+	very low certainty of evidence ^[83]

The reality did not match the promise. To begin, as Dr. Coleman wrote, “we were not able to be as systematic as we could have been (e.g., we did not use GRADE explicitly).”⁸⁴ Dr. Karasic, the chair of the mental health chapter, testified that rather than relying on systematic reviews, some drafters simply “used authors ... we were familiar with.”⁸⁵

WPATH also decided not to differentiate “between statements based on [literature reviews] and the rest,”⁸⁶ and ordered the removal of all notations disclosing the quality of evidence for each recommendation. A draft of the hormone chapter illustrates the change. The chapter had initially offered a “weak recommendation” (“we suggest”) based on low-

⁸¹ *Id.*

⁸² *Id.*

⁸³ WPATH, *Methodology for the Development of SOC8*, <https://perma.cc/QD95-754H>.

⁸⁴ Ex.190(Doc.700-18):8; *see* Ex.182(Doc.700-11):157-58.

⁸⁵ Ex.39(Doc.592-39):66:2–67:5.

⁸⁶ Ex.182(Doc.700-11):62; *see* Ex.9(Doc.700-2):¶¶29-36, 43-47.

quality evidence (“++”) that clinicians prescribe cross-sex hormones to gender dysphoric adolescents, “preferably with parental/guardian consent.”⁸⁷

At first, WPATH seemed to just remove the evidence notations. But then the recommendations themselves appeared to morph from weak (“we suggest”) to strong (“we recommend”). So it was in the adolescent chapter, where all but one recommendation is now “strong”⁸⁸—even as those recommendations are surrounded by admissions that “[a] key challenge in adolescent transgender care is the quality of evidence,” with “the numbers of studies ... still [so] low” that “a systematic review regarding outcomes of treatment in adolescents” is purportedly “not possible.”⁸⁹ And so it was in the hormone chapter, where the final version of the above statement transformed into a strong “we recommend.”⁹⁰

While this mismatch may not seem like a big deal, the difference between a “strong” and “weak” recommendation is important, particularly when it comes to life-altering interventions like cross-sex hormones. Under GRADE, “low” or “very-low” quality evidence means, respectively, that the true effect of the medical intervention may, or is likely to be, “substantially different” from the estimate of the effect based on the available evidence.⁹¹ Thus, given that the estimated effect is therefore likely to be *wrong* for very low-quality evidence, it is imperative for clinicians to know the quality of evidence supporting a

⁸⁷ Ex.182(Doc.700-11):5; *see id.* at 1-40; Ex.9(Doc.700-2):¶¶29-36, 43-47.

⁸⁸ SOC-8, *supra* note 11, at S48.

⁸⁹ *Id.* at S46-47.

⁹⁰ *Id.* at S111.

⁹¹ Howard Balshem *et al.*, *GRADE Guidelines*, 64 J. CLINICAL EPIDEMIOLOGY 401, 404 (2011), <https://perma.cc/2KDY-6BW5>.

treatment recommendation—and why, with certain exceptions not applicable here, evidence-based medicine warns against “strong” recommendations based on low-quality evidence.⁹² So it is a big deal indeed that WPATH promised clinicians that it followed this system when it actually eschewed transparency and made “strong” recommendations no matter what the evidence said.

C. WPATH Hindered Publication of Evidence Reviews.

Though the SOC-8 authors and their advocacy allies didn’t seem to have much use for them, the Johns Hopkins evidence-review team “completed and submitted reports of reviews (dozens!) to WPATH” for SOC-8.⁹³ The results were concerning. In August 2020, the head of the team, Dr. Robinson, wrote to the Agency for Healthcare Research and Quality at HHS about their research into “multiple types of interventions (surgical, hormone, voice therapy...).”⁹⁴ She reported: “[W]e found little to no evidence about children and adolescents.”⁹⁵

Dr. Robinson also informed HHS that she was “having issues with this sponsor”—WPATH—“trying to restrict our ability to publish.”⁹⁶ Days earlier, WPATH had rejected Robinson’s request to publish two manuscripts because her team failed to comply with WPATH’s policy for using SOC-8 data.⁹⁷ Among other things, that policy required the

⁹² Liang Yao *et al.*, *Discordant and Inappropriate Discordant Recommendations*, BMJ (2021), <https://perma.cc/W7XN-ZELX>.

⁹³ Ex.173 (Doc.560-23):22-25.

⁹⁴ *Id.* at 24.

⁹⁵ *Id.* at 22.

⁹⁶ *Id.*

⁹⁷ Ex.167(Doc.560-17):86-88.

team to seek “final approval” of any article from an SOC-8 leader and then from the WPATH Board of Directors.⁹⁸ It also mandated that authors “use the Data for the benefit of advancing transgender health in a positive manner” (as defined by WPATH) and “involve[] at least one member of the transgender community in the design, drafting of the article, and the *final approval* of the article.”⁹⁹ Once those boxes were checked, the WPATH Board of Directors had final authority on whether the manuscript could be published.¹⁰⁰

This is an alarming amount of editorial control over publication of a systematic review, the entire purpose of which is to provide an objective and neutral review of the evidence. But WPATH justified its oversight by reasoning that it was of “paramount” importance “that any publication based on WPATH SOC8 data [be] thoroughly scrutinized and reviewed to ensure that publication does not negatively affect the provision of transgender healthcare in the broadest sense” (as WPATH defined it).¹⁰¹ But to make the process *appear* neutral, WPATH imposed one last requirement: Authors had to “acknowledge[]” in their manuscript that they were “solely responsible for the content of the manuscript, and the manuscript does not necessarily reflect the view of WPATH.”¹⁰²

⁹⁸ *Id.* at 37-38, 75-81.

⁹⁹ *Id.* at 37 (emphasis added).

¹⁰⁰ *Id.* at 38.

¹⁰¹ *Id.* at 91.

¹⁰² *Id.* at 38.

WPATH eventually allowed the Johns Hopkins team to publish two of its manuscripts. (It's still unclear what happened to the others.¹⁰³) The team dutifully reported that the “authors”—not WPATH—were “responsible for all content.”¹⁰⁴

D. WPATH Recommends Castration as “Medically Necessary” for “Eunuchs.”

As if to drive home how unscientific the SOC-8 enterprise was, WPATH included an entire chapter on “eunuchs”—“individuals assigned male at birth” who “wish to eliminate masculine physical features, masculine genitals, or genital functioning.”¹⁰⁵ Because eunuchs “wish for a body that is compatible with their eunuch identity,” WPATH recommends “castration to better align their bodies with their gender identity.”¹⁰⁶ That’s not an exaggeration. When asked at his deposition whether “in the case of a physically healthy man with no recognized mental health conditions and who presents as a eunuch seeking castration, but no finding is made that he’s actually at high risk of self-castration, nevertheless, WPATH’s official position is that that castration may be a medically necessary procedure?”, Dr. Coleman confirmed: “That’s correct.”¹⁰⁷

Dr. Coleman also admitted that no diagnostic manual recognizes “eunuch” as a medical or psychiatric diagnosis.¹⁰⁸ And other SOC-8 authors criticized the chapter as “very

¹⁰³ Cf. Ex.167(Doc.560-17):91.

¹⁰⁴ Kellan Baker *et al.*, *Hormone Therapy, Mental Health, and Quality of Life*, 5 J. ENDOCRINE SOC’Y 1, 3 (2021); L. Wilson, *Effects of Antiandrogens on Prolactin Levels Among Transgender Women*, 21 INT’L J. TRANSGENDER HEALTH 391, 392 (2020).

¹⁰⁵ SOC-8, *supra* note 11, at S88.

¹⁰⁶ *Id.* at S88-89.

¹⁰⁷ Ex.21(Doc.700-3):172:19–173:25.

¹⁰⁸ *Id.*

high on speculation and assumptions, whilst a robust evidence base is largely absent.”¹⁰⁹ Dr. Bowers even admitted that not every board member read the chapter before approving it for publication.¹¹⁰ No matter: The guideline that Plaintiffs rely on to ask this Court to reverse the trial court’s factual findings recommends castration for men and boys who identify as “eunuch.”

And how did WPATH learn that castration constitutes “medically necessary gender-affirming care”?¹¹¹ From the internet—specifically a “large online peer-support community” called the “Eunuch Archive.”¹¹² According to SOC-8 itself, the “Archive” contains “the greatest wealth of information about contemporary eunuch-identified people.”¹¹³ The guideline does not disclose that part of the “wealth” comes in the form of the Archive’s fiction repository, which hosts thousands of stories that “focus on the eroticization of child castration” and “involve the sadistic sexual abuse of children.”¹¹⁴ “The fictional pornography” “includes themes such as Nazi doctors castrating children, baby boys being fed milk with estrogen in order to be violently sex trafficked as adolescents, and pedophilic fantasies of children who have been castrated to halt their puberty.”¹¹⁵

¹⁰⁹ Ex.182(Doc.700-11):96.

¹¹⁰ Ex.18(Doc.564-8):147:9–148:4; *Boe*.MSJ(Doc.619):16.

¹¹¹ SOC-8, *supra* note 11, at S88.

¹¹² *Id.*

¹¹³ *Id.*

¹¹⁴ Genevieve Gluck, *Top Trans Medical Association Collaborated with Castration, Child Abuse Fetishists*, REDUXX (May 17, 2022), <https://perma.cc/5DWF-MLRU>.

¹¹⁵ *Id.*

Despite all this, Plaintiffs assure the Court that the WPATH standards are “well-established, widely accepted,” and viewed as “authoritative[] by the major medical organizations in the United States.” Plfs’ Op. Br. 24. If true, that is pretty good evidence for why Missouri had to regulate an area of medicine that medical organizations had abandoned to the activists.

III. WPATH Acts Like An Advocacy Organization, Not A Medical One.

As is clear by now, though WPATH cloaks itself in the garb of evidence-based medicine, its heart is in advocacy. (Indeed, in its attempt to avoid discovery into its “evidence-based” guideline, WPATH told the district court in Alabama it was just a “nonparty advocacy organization[].”¹¹⁶) That was evident after SOC-8 was published, when Dr. Coleman circulated an internal “12-point strategic plan to advance gender affirming care.”¹¹⁷ He began by identifying “attacks on access to trans health care,” which included (1) “academics and scientists who are naturally skeptical,” (2) “parents of youth who are caught in the middle of this controversy,” (3) “continuing pressure in health care to provide evidence-based care,” and (4) “increasing number of regret cases and individuals who are vocal in their retransition who are quick to blame clinicians for allowing themselves to transition despite an informed consent process.”¹¹⁸

To combat these “attacks” from “evidence-based medicine” and aggrieved patients, Dr. Coleman encouraged WPATH to ask other medical organizations to formally endorse

¹¹⁶ Mot. to Quash at 3, *Boe*, 2:22-cv-184 (M.D. Ala. Dec. 27, 2022), Doc.208.

¹¹⁷ Ex.190(Doc.700-18):5 (capitalization altered).

¹¹⁸ *Id.*; see Ex.16(Doc.557-16):¶103.

SOC-8. He noted that the statement “that the SOC has so many endorsements has been an extremely powerful argument” in court, particularly given that “[a]ll of us are painfully aware that there are many gaps in research to back up our recommendations.”¹¹⁹ Problem was, Dr. Coleman “ha[d] no idea how it was ever said that so many medical organizations ha[d] endorsed” the standards.¹²⁰ He suspected that organizations had only “referenced” the guideline but “never formally endorsed” it.¹²¹

So Dr. Coleman and other WPATH leaders made a concerted effort to obtain formal endorsements from other organizations. At his deposition in May 2024, Dr. Coleman knew of only two organizations that had endorsed SOC-8: the World Association for Sexual Health and the International Society for Sexual Medicine.¹²² The AAP, Dr. Coleman said, rejected WPATH’s request.¹²³ So did the American Medical Association, which told WPATH that it “does not endorse or support standards of care—that falls outside of our expertise.”¹²⁴ The response caused Dr. Bouman to complain that the AMA is run by “white cisgender heterosexual hillbillies from nowhere.”¹²⁵

Then there is WPATH’s response to the Cass Review, discussed by the trial court below. Rather than embracing one of “the most comprehensive, evidence-based reviews of

¹¹⁹ Ex.190(Doc.700-18):5-6.

¹²⁰ *Id.*

¹²¹ *Id.* at 6 (spelling corrected).

¹²² Ex.21(Doc.700-3):261:5-12, 262:4-8; *see* Ex.190(Doc.700-18):6.

¹²³ Ex.21(Doc.700-3):261:20-23; Ex.188(Doc.700-17):152.

¹²⁴ Ex.189(Doc.560-39):15.

¹²⁵ *Id.* at 13; Ex.21(Doc.700-3):259:4-10.

a medical service from the long history of such independent investigations” in the UK,¹²⁶ WPATH seems to view NHS England and the Cass Review as simply more “attacks on access to trans health care.” In its public “comment on the Cass Review,” for instance, WPATH defends SOC-8 against the Review’s harsh assessment by boasting that its guideline was “based on far more systematic reviews tha[n] the Cass Review.”¹²⁷ That may or may not be true—Dr. Robinson did say her team had conducted “dozens!” of reviews—but it’s a rich claim for WPATH to make given that it went to such great lengths to restrict its own evidence review team from publishing its findings, WPATH did not otherwise make a *single* review or evidence table from SOC-8 available to the public, and SOC-8 states that WPATH found insufficient evidence to even conduct a systematic review for the adolescent chapter. By contrast, the six systematic evidence reviews and two appraisals of international clinical guidelines conducted through an open procurement process by the University of York for the Cass Review are freely available in the peer-reviewed *Archives of Disease in Childhood*.¹²⁸ WPATH’s critique of the Cass Review is simply not serious.

It is also not unusual. WPATH has long sought to ensure that only one side of the story is told, and it critiques or silences those who offer opposing viewpoints to the public.¹²⁹ For instance, at its inaugural conference in 2017, USPATH—WPATH’s U.S.

¹²⁶ C. Ronny Cheung et al., *Gender Medicine and the Cass Review: Why Medicine and the Law Make Poor Bedfellows*, ARCH. DIS. CHILD 1-2 (Oct. 2024), <https://perma.cc/X7CH-NM7U>.

¹²⁷ WPATH and USPATH Comment on the Cass Review (May 17, 2024), <https://perma.cc/B2TU-ALSR>.

¹²⁸ And online: <https://adc.bmj.com/pages/gender-identity-service-series>.

¹²⁹ See generally Ex.16(Doc.557-16).

affiliate—bowed to the demands of trans-activist protestors and cancelled a panel presentation by a respected researcher, Dr. Ken Zucker, who attempted to present research showing that most children with gender dysphoria will have the dysphoria “desist” by adulthood.¹³⁰ A few years later, USPATH formally censured its president, Dr. Erica Anderson, for publicly discussing concerns about “sloppy” care resulting from gender dysphoric youth being “[r]ushed through the medicalization” of transitioning treatments.¹³¹ WPATH even issued a formal statement “oppos[ing] the use of the lay press ... as a forum for the scientific debate” over “the use of puberty delay and hormone therapy for transgender and gender diverse youth.”¹³² As Dr. Bowers explained it: “[T]he public ... doesn’t need to sort through all of that.”¹³³

The result of WPATH’s flavor of advocacy has been predictable. One of the authors of SOC-8’s adolescent chapter was prescient in her concern: “My fear is that if WPATH continues to muzzle clinicians and relay the message to the public that they have no right to know about the debate, WPATH will become the bad guy and not the trusted source.”¹³⁴

¹³⁰ See Ex.16(Doc.557-16):¶¶9-13; Ex.39(Doc.592-39):187:23–188:5; Ex.178(Doc.700-7):5.

¹³¹ Ex.176(Doc.700-5):107, 113-14; Ex.16(Doc.557-16):¶¶14-17; Abigail Shrier, *Top Trans Doctors Blow the Whistle on “Sloppy” Care*, THE FREE PRESS (Oct. 4, 2021), <https://perma.cc/R7M3-XTQ3>.

¹³² Joint Letter from USPATH and WPATH (Oct. 12, 2022), <https://perma.cc/X7ZN-G6FS>.

¹³³ Ex.18(Doc.564-8):287:18-22; *Boe*.MSJ(Doc.619):22.

¹³⁴ Ex.176(Doc.700-5):152.

* * *

Much more could be said about how untrustworthy Plaintiffs' favorite medical organization is. But it is worth emphasizing that WPATH's insistence on advocacy over patient welfare has a human cost that its own leaders have seen firsthand. As Dr. Bowers recounted in a private email to other WPATH leaders (apologizing for going public with concerns about puberty blockers):

Like my [female genital mutilation] patients who had never experienced orgasm, the puberty blockaded kids did not know what orgasm might feel like and most experienced sensation to their genitalia no differently than if it had been a finger or a portion of their thigh.... My concern culminated during a pre-surgical evaluation on a young trans girl from a highly educated family whose daughter responded when I asked about orgasm, "what is that?" The parents countered with, "oh honey, didn't they teach you that in school?" I felt that our informed consent process might not be enough.... It occurred to me that how could anyone truly know how important sexual function was to a relationship, to happiness? It isn't an easy question to answer....¹³⁵

So it isn't. That is why States routinely set age limits on risky endeavors, be it driving a car, buying a beer, or consenting to a hysterectomy. Undergoing sex-change procedures is no different. As Dr. Coleman privately recognized, "at their age – they would not know what they want."¹³⁶

CONCLUSION

The Court should affirm.

¹³⁵ Ex.176(Doc.700-5):68.

¹³⁶ Ex.180(Doc.700-9):59.

Respectfully submitted,

s/ Timothy Belz

Timothy Belz, #31808

CLAYTON PLAZA LAW GROUP, L.C.

112 South Hanley, Second Floor

St. Louis, Missouri 63105-3418

Phone: (314) 726-2800

Fax: (314) 863-3821

tbelz@olblaw.com

Steve Marshall

Alabama Attorney General

A. Barrett Bowdre*

Principal Deputy Solicitor General

STATE OF ALABAMA

OFFICE OF THE ATTORNEY GENERAL

501 Washington Avenue

Montgomery, Alabama 36130-0152

Telephone: (334) 242-7300

Fax: (334) 353-8400

Barrett.Bowdre@AlabamaAG.gov

*Motion for *pro hac vice* admission
forthcoming

SEPTEMBER 2, 2025

Additional Counsel for Amici Curiae Listed on Next Page

ADDITIONAL COUNSEL

STEPHEN J. COX Attorney General State of Alaska	LIZ MURRILL Attorney General State of Louisiana	JONATHAN SKRMETTI Attorney General & Reporter State of Tennessee
TIM GRIFFIN Attorney General State of Arkansas	LYNN FITCH Attorney General State of Mississippi	KEN PAXTON Attorney General State of Texas
JAMES UTHMEIER Attorney General State of Florida	AUSTN KNUDSEN Attorney General State of Montana	DEREK BROWN Attorney General State of Utah
CHRIS CARR Attorney General State of Georgia	MICHAEL T. HILGERS Attorney General State of Nebraska	JASON MIYARES Attorney General Commonwealth of Virginia
RAÚL R. LABRADOR Attorney General State of Idaho	DREW H. WRIGLEY Attorney General State of North Dakota	JOHN B. MCCUSKEY Attorney General State of West Virginia
THEODORE E. ROKITA Attorney General State of Indiana	DAVE YOST Attorney General State of Ohio	KEITH G. KAUTZ Attorney General State of Wyoming
BRENNNA BIRD Attorney General State of Iowa	GENTNER DRUMMOND Attorney General State of Oklahoma	
KRIS W. KOBACH Attorney General State of Kansas	ALAN WILSON Attorney General State of South Carolina	
RUSSELL COLEMAN Attorney General Commonwealth of Kentucky	MARTY JACKLEY Attorney General State of South Dakota	

CERTIFICATE OF SERVICE AND COMPLIANCE

I certify that a true and correct copy of the foregoing was filed electronically and served by operation of the Court's electronic filing system this 2nd day of September, 2025, on all registered parties, and that I signed the original and that it otherwise contains the information required by Rule 55.03 and includes information on how the brief was served on other parties, Mo. R. Civ. P. I also certify that the foregoing brief complies with the formatting instructions in Rule 84.03, Mo. R. Civ. P., and the limitations in Rule 84.06(b), Mo. R. Civ. P., and that the brief contains 6,804 words, excluding the cover, certificates required by Rule 84.06(c), and signature block.

s/ Timothy Belz
Timothy Belz